Cargando…

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare type of thyroid cancer; however, it accounted for 13.4% of the disease-specific mortalities. ALTER01031 (NCT02586350) was a randomised, placebo-controlled phase 2b trial that evaluated the efficacy and safety of anlotinib in locally advanced or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jingzhu, Chi, Yihebali, Hu, Chuanxiang, Chen, Xiaohong, Ge, Minghua, Zhang, Yuan, Guo, Zhuming, Wang, Jun, Chen, Jie, Zhang, Jiewu, Cheng, Ying, Li, Zhendong, Liu, Hui, Qin, Jianwu, Zhu, Jingqiang, Cheng, Ruochuan, Xu, Zhengang, Li, Dapeng, Tang, Pingzhang, Gao, Ming, Zheng, Xiangqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722716/ https://www.ncbi.nlm.nih.gov/pubmed/36483043 http://dx.doi.org/10.3389/fonc.2022.852032

Ejemplares similares

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

Ultrasound features of medullary thyroid cancer as predictors of biological behavior
por: Zhao, Jingzhu, et al.
Publicado: (2021)

2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma
por: Gao, Ming, et al.
Publicado: (2017)

Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer
por: Hao, Weijing, et al.
Publicado: (2023)

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF(V600E) Mutations
por: Su, Yanjun, et al.
Publicado: (2021)

2017 Chinese expert consensus on the clinical application of serum marker for thyroid cancer
por: Gao, Ming, et al.
Publicado: (2018)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer
por: Yu, Yang, et al.
Publicado: (2015)

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Zheng, Xiangqian, et al.
Publicado: (2021)

Design of new drugs for medullary thyroid carcinoma
por: Li, Yanqing, et al.
Publicado: (2022)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
por: Sun, Yongkun, et al.
Publicado: (2016)

Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
por: Cheng, Ke, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause
por: Hou, Xiukun, et al.
Publicado: (2023)

Prevention and Treatment of Life-Threatening Bleeding After Thyroid Surgery
por: Zhang, Xiwei, et al.
Publicado: (2015)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer
por: Wu, Jiajun, et al.
Publicado: (2023)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study
por: Yin, Jun, et al.
Publicado: (2023)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors
por: Chi, Jiadong, et al.
Publicado: (2017)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020)

Efficacy of Superselective Neck Dissection in Detecting Metastasis in Patients with cN0 Papillary Thyroid Carcinoma at High Risk of Lateral Neck Metastasis
por: An, Changming, et al.
Publicado: (2017)

Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma
por: Jiang, Ke, et al.
Publicado: (2016)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
por: Zheng, Xiangqian, et al.
Publicado: (2019)

Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer
por: Fang, Shencun, et al.
Publicado: (2020)

Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET/CT: a network meta-analysis and systematic review
por: Li, Pengyu, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
por: Zhi, Jingtai, et al.
Publicado: (2017)

Bronchial Fistula: Rare Complication of Treatment with Anlotinib
por: DENG, Pengbo, et al.
Publicado: (2020)

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial
por: Lu, Shun, et al.
Publicado: (2023)

TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib
por: Lin, Cheng, et al.
Publicado: (2023)

Successful treatment of advanced ovarian cancer with anlotinib: a case report
por: Zhang, Ping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o1tp67so915kopfms8ov2kptlf